RECRUITING

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Extensive research is being conducted in search of neuroprotective agents for possible use in the acute phase of stroke and agents that can be used for neurorepair in later stages of stroke. Several trials have been conducted and are in progress using different pharmacological agents, but none of the studies involve the stimulation of ETB receptors to treat cerebral ischemic stroke. Sovateltide (IRL-1620, PMZ-1620) has been effective in animal models of cerebral ischemic stroke. Its safety and tolerability have been demonstrated in a human phase I study with 7 subjects. Clinical phase II and III results indicate that sovateltide is a novel, first-in-class, highly effective drug candidate for treating cerebral ischemic stroke. Safety and significant efficacy in improving the National Institutes of Health Stroke Scale (NIHSS), Modified Rankin scale (mRS), and Barthel index (BI) obtained in phase II and III studies in patients with cerebral ischemic stroke in India are convincing and encouraged us to investigate its safety and efficacy in cerebral ischemic stroke patients in the United States. Therefore, the plan is to conduct a phase III clinical study to evaluate the safety and efficacy of sovateltide therapy along with standard of care in patients of acute ischemic stroke.

Official Title

A Multicentric, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke.

Quick Facts

Study Start:2025-07-26
Study Completion:2026-11
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05691244

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Adult males or females aged 18 - 80 years of age.
  2. 2. Consent obtained per national laws and regulations, and in accordance with the applicable ethics committee requirements prior to study procedures.
  3. 3. A stroke is ischemic in origin that is diagnosed clinically and/or radiologically confirmed by Computed Tomography (CT) scan or diagnostic magnetic resonance imaging (MRI) prior to enrolment. No hemorrhage as proved by cerebral CT/MRI scan.
  4. 4. Cerebral ischemic stroke patients presenting within 24 hours after the onset of symptoms with NIHSS score of ≥8 and \<20, NIHSS Level of Consciousness (1A) score \<2 at the time of screening. This includes cerebral ischemic stroke patients who completely recovered from earlier episodes before having a new or fresh stroke having a pre-stroke historical measure of mRS score of 0-2.
  5. 5. The patient is \<24 hours from the time of stroke onset when the first dose of sovateltide is administered. Time of onset is when symptoms began; for stroke that occurred during sleep, time of onset is when the patient was last seen or was self- reported to be normal.
  6. 6. Reasonable expectation of availability to receive the full sovateltide/placebo course of therapy and to be available for subsequent follow-up visits.
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Anil Gulati, MD, PhD
CONTACT
6307806087
anil.gulati@pharmazz.com
Neil Marwah, MD
CONTACT
6307806087
neil.marwah@pharmazz.com

Principal Investigator

Anil Gulati, MD, PhD
STUDY_CHAIR
Pharmazz, Inc.

Study Locations (Sites)

The University of Arizona - College of Medicine
Tuscon, Arizona, 85719
United States
St. John's Regional Medical Center
Oxnard, California, 93030
United States
Intercoastal Medical Group
Sarasota, Florida, 34239
United States
Hackensack University Medical Center
Paramus, New Jersey, 07652
United States
Guilford Neurologic Associates
Greensboro, North Carolina, 27405
United States
OSU Wexner Medical Center
Columbus, Ohio, 43210
United States
UPMC Presbyterian Hospital
Pittburgh, Pennsylvania, 15219
United States
CHI Memorial Neuroscience Institute
Chattanooga, Tennessee, 37404
United States
Houston Methodist Hospital Neurological Institute
Houston, Texas, 77030
United States

Collaborators and Investigators

Sponsor: Pharmazz, Inc.

  • Anil Gulati, MD, PhD, STUDY_CHAIR, Pharmazz, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-07-26
Study Completion Date2026-11

Study Record Updates

Study Start Date2025-07-26
Study Completion Date2026-11

Terms related to this study

Keywords Provided by Researchers

  • Endothelin B Receptors

Additional Relevant MeSH Terms

  • Acute Ischemic Stroke
  • Cerebral Stroke